Volume 24, Issue 2 (June 2020)                   Physiol Pharmacol 2020, 24(2): 133-141 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hafazeh L, Changizi-Ashtiyani S, Najafi H, Ghasemi F, Rahjoo T, Babaei S et al . Therapeutic effects of adipose-derived mesenchymal stem cells on gentamicin-induced renal failure. Physiol Pharmacol 2020; 24 (2) :133-141
URL: http://ppj.phypha.ir/article-1-1527-en.html
Abstract:   (2078 Views)
Introduction: Considering the limitations of conventional therapeutic methods in renal failure, researchers are paying attention to the application of adipose-derived mesenchymal stem cells (AD-MSCs) and their protective effects against acute renal failure. This study aims to assess the therapeutic effects of AD-MSCs in gentamicin-induced renal failure in rats. Methods: In this study, 40 male Wistar rats were studied in control, sham, gentamicin treated with and without receiving AD-MSCs. After 10 days, blood samples were collected and hemodynamic parameters, malondialdehyde and ferric reducing antioxidant power (FRAP) measured in the right and left kidneys underwent histologic examination. Results: Gentamicin administration significantly increased plasma creatinine, blood urea nitrogen, oxidative stress parameters and histologic damages; while significantly reduced FRAP in the gentamicin-receiving group in comparison with the sham group. AD-MSCs treatment significantly improved renal function parameters, oxidative stress and histologic damages in comparison with the gentamicin receiving group. Conclusion: Intravenous injection of AD-MSCs in gentamicin-induced renal failure improved renal function, oxidative stress parameters and histologic damages.
Full-Text [PDF 1164 kb]   (838 Downloads)    

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.